SIETES :: 92261 citas

Resultados de la búsqueda por CONSULTA TERAPÉUTICA REFINAR BÚSQUEDA

1.

Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA 2017;318:1700-1. [Ref.ID 102140]

2.

Bérard A, Sheehy O, Zhao J-P, Vinet É, Bernatsky S, Abrahamowicz M. SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn. Br J Clin Pharmacol 2017;83:1126-33. [Ref.ID 101973]

3.

Salat D, Llop R, Aguilera C, Danés I, Bosch M, Asensio C, Castañeda F, Esterlich E, Vallano A. Therapeutics enquiries about biological agents as a tool to identify safety aspects and patterns of use. European Journal of Hospital Pharmacy 2016;23:161-5. [Ref.ID 100163]

4.

Taegtmeyer AB, Curkovic I, Rufibach K, Corti N, Battegay E, Kullak-Ublick GA. Electronic prescribing increases uptake of clinical pharmacologists' recommendations in the hospital setting. Br J Clin Pharmacol 2011;72:958-64. [Ref.ID 91875]

5.

Erdeljic V, Francetic I, Makar-Ausperger K, Likic R, Radacic-Aumiler M. Clinical pharmacology consultation: a better answer to safety issues of drug therapy during pregnancy?. Eur J Clin Pharmacol 2010;66:1037-46. [Ref.ID 89445]

6.

Gendron MP, Martin B, Oraichi D, Bérard A. Health care providers' requests to Teratogen Information Services on medication use during pregnancy and lactation. Eur J Clin Pharmacol 2009;65:523-31. [Ref.ID 85831]

7.

Hedegaard U, Damkier P. Problem-oriented drug information: physicians' expectations and impact on clinical practice. Eur J Clin Pharmacol 2009;65:515-22. [Ref.ID 85830]

8.

Frost Widnes SK, Schjott J. Drug use in pregnancy - physician's evaluation of quality and clinical impact of drug information centres. Eur J Clin Pharmacol 2009;65:303-8. [Ref.ID 85449]

9.

López F, Romans C, Aguilera C. Therapeutic consultation service about teratogens. A pilot study. Basic Clin Pharmacol Toxicol 2006;99:46. [Ref.ID 78400]

10.

Durán M, Pérez E, Ballarín E, Vidal X, Laporte JR, Capellà D. Therapeutic use of cannabis: review and synthesis of the evidence, information, and institutional collaborative research in Catalonia. Basic Clin Pharmacol Toxicol 2006;99:24. [Ref.ID 78388]

11.

Sullivan F, Wyatt JC. Is a consultation needed?. BMJ 2005;331:625-7. [Ref.ID 74813]

12.

Bergk V, Gasse C, Schnell R, Haefeli WE. Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 2004;60:595-602. [Ref.ID 71969]

13.

von Mach MA, Meyer S, Omogbehin B, Kann PH, Weilemann LS. Epidemiological assessment of 160 cases of insulin overdose recorded in a regional poisons unit. Int J Clin Pharmacol Ther 2004;42:277-80. [Ref.ID 70114]

14.

Eklöf AC, Thurelius AM, Garle M, Rane A, Sjöqvist F. The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol 2003;59:571-7. [Ref.ID 68148]

15.

Haller CA, Anderson IB, Kim SY, Blanc PD. An evaluation of selected herbal reference texts and comparison to published reports of adverse herbal events. Adverse Drug React Toxicol Rev 2002;21:143-50. [Ref.ID 62144]

16.

Figueras A, Laporte JR. Therapeutic consultation centres are helpful in developing countries. BMJ 2002;324:236. [Ref.ID 60218]

17.

Pedrós C, Agustí A. La consulta farmacoterapéutica como fuente para detectar y prevenir reacciones adversas a medicamentos en el ámbito hospitalario. Archivos de la Facultad de Medicina de Zaragoza 2001;41:21-3. [Ref.ID 56585]

18.

Brassey J, Elwyn G, Price C, Kinnersley P. Just in time information for clinicians: a questionnaire evaluation of the ATTRACT project. BMJ 2001;322:529-30. [Ref.ID 55395]

19.

Agustí A, Aguilera C, Danés I, Vidal X, Arnau JM, Laporte JR. La consulta terapèutica: una eina complementària d'informació per a la individualització de la terapèutica. Annals Med (Barc) 2000;83:223-7. [Ref.ID 52594]

20.

Hereu P, Agustí A. Tratamiento antitrombótico en el stent coronario. Med Clin (Barc) 2000;114:113-4. [Ref.ID 49116]